NCT06284486View on ClinicalTrials.gov

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

Given by PO

DRUG

Revumenib

Given by PO

Trial Locations (4)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21218

RECRUITING

Johns Hopkins University, Baltimore

77030

RECRUITING

MD Anderson Cancer Center, Houston

02215

RECRUITING

Dana-Farber Cancer Center, Boston

Sponsors
All Listed Sponsors
collaborator

Syndax Pharmaceuticals

INDUSTRY

collaborator

AbbVie

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER